Cerevel Therapeutics Holdings, Inc. (CERE)

24.39 +0.42 (+1.75%) At close: 04:00PM EDT

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
https://www.cerevel.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 285

Key executives

Name	Title	Pay	Exercised	Year born
Dr. N. Anthony Coles Jr., M.P.H.	Exec. Chairman & CEO	1.01M	N/A	1960
Mr. Abraham N. Ceesay M.B.A.	Pres	776.64k	N/A	1978
Mr. Mark Bodenrader	Interim CFO, VP of Fin. & Chief Accounting Officer	440.89k	N/A	1973
Mr. Scott M. Akamine J.D.	Chief Legal Officer & Corp. Sec.	444.74k	N/A	1985
Dr. Ramiro Sanchez M.D.	Chief Medical Officer	716.29k	N/A	1961
Dr. John J. Renger Ph.D.	Chief Scientific Officer	N/A	N/A	1969
Mr. Matthew Calistri	VP of Investor Relations	N/A	N/A	N/A
Mr. Kenneth A. DiPietro	Chief HR Officer	N/A	N/A	1959
Ms. Kathleen Tregoning M.A.	Chief Corp. Affairs Officer	N/A	N/A	1971

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cerevel Therapeutics Holdings, Inc.’s ISS governance QualityScore as of 1 February 2023 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.